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Abstract
Pulmonary infections are important causes of global morbidity and mortality, but diagnostics are 
often limited by the ability to collect specimens easily, safely and in a cost-effective manner. We 
review recent advances in the collection of infectious aerosols from patients with tuberculosis and 
with influenza. Although this research has been focused on assessing the infectious potential of 
such patients, we propose that these methods have the potential to lead to the use of patient-
generated microbial aerosols as non-invasive diagnostic tests of disease as well as tests of 
infectiousness.
Introduction
Pulmonary infections are major public health problems globally, with tuberculosis (TB) the 
most lethal infectious disease and lower respiratory infections the 4th leading cause of death. 
In the United States, pneumonia and influenza together are the 8th leading cause of death. 
Despite considerable technological advances in molecular diagnostics and in clinical 
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microbiology, the diagnosis of pulmonary infections is limited by the ability to easily obtain 
adequate specimens in a safe and cost-effective manner. There have been advances in the 
collection of infectious aerosols over the past two decades, especially in the research of 
tuberculosis and influenza. We will briefly review these advances, and we propose that 
patientgenerated aerosols have the potential to become clinically useful specimens for the 
diagnosis of pulmonary infections in the near future.
The most commonly used specimen to diagnose pulmonary infections currently is 
expectorated sputum. However, sputum production varies immensely across diseases. It is 
usually available either spontaneously or by induction with inhaled saline in HIV-negative 
adults presenting with pulmonary TB or with exacerbations of bronchiectasis due to cystic 
fibrosis. In contrast, about 50% of patients with nontuberculous mycobacterial infections 
associated with nodular bronchiectasis are unable to produce sputum, and about one-third of 
patients with bacterial pneumonia may not produce sputum.
The utility of sputa specimens for the diagnosis of community-acquired pneumonia remains 
controversial.1 Although outcomes are best when treatment is directed at specific pathogens, 
over 95% of cases of ambulatory pneumonia are successfully treated with empiric antibiotic 
therapy. A critical issue is the quality of the sputum specimen, as many that are collected are 
saliva from the upper respiratory tract and are not representative of the lower respiratory 
tract. Children usually do not produce good quality sputum specimens, so the etiologic agent 
is often inferred by the clinical presentation, epidemiology, and laboratory or radiographic 
patterns. When good quality sputum specimens cannot be obtained, bronchoscopy is often 
indicated, especially if the patient is very ill.
Brief History of Pulmonary Specimens
In 1882, Robert Koch identified what became known as Mycobacterium tuberculosis in 
autopsy tissue and in the sputum from patients suffering from ‘phthisis’, what we know now 
as tuberculosis (TB).2 Sputum has continued to be the most commonly ordered specimen to 
diagnose TB and other respiratory infections globally. Several years after Koch’s discovery, 
face masks were used to collect the aerosols generated by coughing from TB patients in a 
research study, using microscopy to detect the bacilli.3 However, this method was never 
adapted to the collection of clinical specimens.
Although flexible bronchoscopes were developed in the 1960s, it was not until the 1980s 
that they were used routinely to obtain bronchoalveolar lavage (BAL) to diagnose 
respiratory infections, driven largely by the AIDS epidemic.4 The use of sputum induction 
by inhalation of hypertonic saline also increased around this time, especially in attempts to 
non-invasively diagnose Pneumocystis pneumonia and tuberculosis among HIV-infected 
patients. Unfortunately, bronchoscopy is an invasive and relatively expensive procedure that 
is not available in all settings; although typically well-tolerated, it is not without risk. 
Sputum induction is more readily available and less risky, although it can be uncomfortable 
and is not universally available.
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Shortly after Koch’s demonstration that the ‘tubercle bacillus’ was the etiologic agent of TB, 
the discovery of the acid-fast characteristics of the bacillus led to the clinical use of sputum 
microscopy for acid-fast bacilli (AFB), still the method of diagnosing TB in much of the 
world today, 137 years later. The mode of transmission of TB remained controversial for the 
next 80 years until the elegant studies of Riley and colleagues that proved airborne 
transmission by demonstrating that guinea pigs developed TB upon breathing air exhausted 
from a remote experimental ward housing TB patients.5 Thus, Mycobacterium tuberculosis 
bacilli must be in or on particles in the air, i.e., in an ‘aerosol’, a system of particles 
dispersed in the air. In spite of this knowledge that TB is transmitted by airborne bacilli and 
not by sputum, the infectiousness of patients with pulmonary TB (from here on written only 
as ‘TB’) has continued to rely upon the demonstration of AFB in sputum due to the ease of 
sputum testing and the lack of technology to detect airborne bacilli, i.e., infectious aerosols.
In an initial proof of concept study of a novel cough aerosol sampling system (CASS) 
(Figure 1), only 4 of 12 (25%) hospitalized patients with TB produced culturable M. 
tuberculosis from the aerosols generated by voluntary coughing.6 Subsequent cohorts of 
smear-positive culture-proven TB patients from Uganda and Brazil found that 100/233 
(43%) patients produced culturable aerosols and of these 57 (24%) were high aerosol 
producers defined as production of ≥ 10 colony forming units (CFU) of M. tuberculosis 
from aerosol sampling.7-9 Two other studies from South Africa have been done, one using a 
minor modification of the CASS method10 and the other a novel stationary respiratory air 
sampling chamber in which the whole patient sits.11 Infectious aerosol production has been 
found to be only partially related to bacterial burden measured as AFB smear grade or time 
to positivity in liquid culture media, and it appears to decrease rapidly after commencement 
of TB therapy. In studies from Brazil and Uganda, aerosol production predicted the risk of 
TB infection among household contacts (HHCs) better than the sputum AFB smear. 
Furthermore, microbiologically-proven secondary TB disease in HHCs clustered among 
contacts of aerosol positive TB cases.
The finding of cough aerosol cultures collected from patients in South Africa with 
extensively drug-resistant refractory to treatment suggests the worrisome potential for 
ongoing transmission.10 The results of cough aerosol cultures from two different groups of 
investigators in South Africa have been similar to those found in Uganda and Brazil by 
another team. The use of polymerase chain reaction (PCR) assays that have identified 
molecular signals in exhaled breath at higher concentrations than the colony-forming units in 
solid cultures.11 A group from the UK has developed a novel method of mask aerosol 
collection of M. tuberculosis using a modified face mask (Figure 2).12 They have also found 
high concentrations of M. tuberculosis DNA in the exhaled breath of TB patients using 
molecular methods. The discordance between the results of the molecular assays versus 
culture-based methods is likely due to differences in viability of the bacilli in the aerosols. It 
is possible that bacilli are in a viable but nonculturable state after exposure to the stresses of 
aerosolization, desiccation and temperature change, as can occur after exposure to hypoxia 
or antibiotics, but this warrants further research.
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Influenza is thought to be spread at least in part by contact and droplets. However, increasing 
evidence suggests that airborne transmission by droplet nuclei also plays an important role, 
especially at short ranges. Viral respiratory tract infections are now commonly diagnosed by 
collecting a sample of respiratory mucus and analyzing it with an antigen or PCR-based 
system.13 Currently, the usual methods for obtaining clinical specimens from the respiratory 
tract are nasopharyngeal or oropharyngeal swabs, nasopharyngeal aspirates and nasal 
washes, tracheal aspirates, bronchoalveolar lavage, or the collection of sputum. Each of 
these techniques has drawbacks: Nasopharyngeal and oropharyngeal swabs, aspirates, and 
washes provide mucus from the upper respiratory tract, which does not always contain the 
same viral load or the same species of viruses as the lower respiratory tract.13 The collection 
of nasopharyngeal swabs is uncomfortable for patients, especially pediatric patients, and 
nasal washes and nasopharyngeal aspirates are often preferred in pediatric practice. 
Bronchoalveolar lavage provides a more definitive sample of lower respiratory tract 
infections, but the procedure is considerably more invasive and unpleasant, and therefore is 
rarely used. Sputum often contains upper respiratory mucus; producing sputum can be 
difficult and distasteful for patients and may require induction by nebulization, which can 
lead to bronchospasm.
The collection of aerosol particles produced by patients during coughing and tidal breathing 
potentially provides a non-invasive method for the collection of diagnostic specimens of 
respiratory viruses. Respiratory viruses have been detected in the exhaled breath and cough 
aerosols from infected patients, especially influenza virus.14,15 Milton and colleagues 
collected the aerosol particles in the exhaled breath and cough of 37 subjects for 30 minutes 
and found influenza virus RNA in 35 samples (95%)(Figure 3).16 Lindsley and colleagues 
collected the particles in three coughs from 47 influenza-positive subjects and detected 
influenza RNA in 38 samples (81%)(Figure 4).15 Milton and colleagues16 and Yan and 
colleagues17 also found that the influenza viral copy numbers in nasopharyngeal swabs were 
at most weakly correlated with the viral copy numbers in aerosol particles, suggesting that 
viral aerosols stem from lung infections, not infections in the head airways. Respiratory 
aerosols therefore might provide a more representative source of diagnostic specimens for 
lower respiratory tract infections than nasopharyngeal swabs.
The biggest challenge to the use of respiratory aerosol analysis as a diagnostic tool is the 
small amount of viral material contained in the aerosols and the subsequent difficulty in the 
detection of viruses. This is especially true for analysis by multiplex PCR assay or genomic 
sequencing, which require larger amounts of material than single-species PCR analysis. In 
their experiments, Yan and colleagues17 found that the influenza viral content collected from 
respiratory aerosols was 104 lower than found in nasopharyngeal swabs. The small amounts 
of viral material in exhaled aerosols leads to a requirement for extended collection times, 
which can present practical difficulties in the clinical setting. The system used by Yan et al. 
collected samples for 30 minutes,17 while the system used by Lindsley et al. required about 
20 minutes.18 Mitchell et al. analyzed filters from patient ventilators, which allowed non-
invasive sample collection for 24 hours.19
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Analysis of exhaled breath aerosols for respiratory viruses also requires a collection method 
suitable for bioaerosols.20 For example, systems that collect exhaled breath condensate do 
not necessarily collect exhaled breath aerosols efficiently,21 and two analyses of exhaled 
breath condensate for respiratory viruses reported poor results.22, 23 Simple filter-based 
bioaerosol collection systems have been used in several respiratory virus studies14, 22, 23 and 
for many applications a filter system would be sufficient when culture is not required. Newer 
systems of exhaled breath aerosol collection allowing normalization to respiratory lining 
fluid volume (by monitoring exhaled droplet volume), size fractionation, and highly efficient 
collection and recovery of aerosol particles may provide clinicians and researchers with new 
tools in the near future.24
Tests of Infectiousness versus Disease
The studies reviewed above were all designed to assess infectiousness, i.e., the potential of 
patients with TB or influenza to transmit to others. However, they were not intended to 
assess the ability of these methods to diagnose disease. In our studies of TB (KF), we have 
observed that there were occasionally positive cough aerosol collections when patients did 
not produce a sputum specimen (unpublished data). Similarly, with influenza patients, we 
have sometimes observed patients with negative nasopharyngeal swabs who had positive 
cough aerosols.15 These observations and the development of increasingly sensitive 
molecular markers suggest the potential of cough or breath aerosols to be used as specimens 
to diagnose disease. Microbial aerosols as diagnostic tests of disease may be especially 
useful for populations where sputum collection is particularly challenging, such as children, 
patients infected with the human immunodeficiency virus (HIV), other immunosuppressed 
patients, and the elderly. As suggested above, microbial aerosols may also be more 
representative of lower respiratory tract disease in viral illnesses in which sputum production 
is not common. Because exhaled aerosol collection is non-invasive, repeated sample 
collection should be more acceptable to patients than traditional methods. If the limitations 
can be overcome, exhaled aerosol analysis could become a useful tool for the diagnosis of 
respiratory infections and for monitoring the course of illness and response to treatment.
Microbial aerosol measurements may prove to be very useful as test of infectiousness for 
infection control or public health officers. For example, the identification of an 
aerosolpositive phenotype of TB patient who could be highly infectious, also known as 
‘superspreaders’, opens the possibility for interventions aimed to prioritize case finding and 
targeted preventive therapy for contacts of high aerosol producers. The development of novel 
point of care tests incorporating polymerase chain reaction (PCR) or other amplification 
methods would enable aerosol sampling to be used to prioritize infection control resources 
within hospitals and other health care facilities, e.g., airborne isolation rooms in resource-
limited settings.
Limitations and Challenges
The major advantages of patient-generated microbial aerosols are that they are collected 
non-invasively and that they likely provide more specific data on infectiousness. However, 
an inherent limitation of the collection of microbial aerosols from either coughs or tidal 
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breathing is the dilution of the pathogens in a large volume of air, compared to the relatively 
concentrated nature of some sputum specimens. This technical limitation was overcome in 
these early studies by collecting large volumes of air and by minimizing additional dilution 
by the entrainment of ambient room air. However, some of those studies were also focused 
on providing data on the particle size distribution of the aerosols to understand the potential 
for deposition within the respiratory tract and for remaining airborne. This goal resulted in 
technologically complex systems that are not appropriate for clinical settings. As the particle 
size data is no longer needed for clinical purposes, future collections can be much simpler. A 
disposable point-of-care device has been developed that collects infectious aerosols onto a 
filter that can be washed,25 but it has only been studied in patients with cystic fibrosis 
(Figure 5). Further development of mask sampling or simple point-of-care devices paired 
with more sensitive diagnostic tests, e.g. molecular assays, will provide the opportunity for 
patientgenerated aerosols to become routine diagnostic specimens.
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Cough Aerosol Sampling System initially used for detection of aerosols of culturable M. 
tuberculosis.. View inside of chamber with two Andersen cascade impactors and settle plate 
(left) and set up in procedure room ready for use (right). (Figure 1. Cough Aerosol Sampling 
System. View inside of chamber with two Andersen cascade impactors and settle plate (left) 
and set up in procedure room ready for use (right).
Reprinted with permission of the American Thoracic Society. Copyright © 2019 American 
Thoracic Society. Fennelly KP, Jones-Lopez EC, Ayakaka I, et al. Variability of infectious 
aerosols produced during coughing by patients with pulmonary tuberculosis. Am J Resp Crit 
Care Med 2012;186;450-457.) The American Journal of Respiratory and Critical Care 
Medicine is an official journal of the American Thoracic Society.
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Mask with filter for sampling of aerosols. (from Williams CML, Cheah ESG, Malkin J, et al. 
Face mask sampling for the detection of Mycobacterium tuberculosis in expelled aerosols. 
PLOS One 2014 9(8): e104921. doi:10.1371/journal.pone.0104921. Although this method 
has been developed for detection of M. tuberculosis, further developments may render it 
useful for detection of other pathogens.
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System for collection of exhaled breath for sampling of influenza aerosols. (Courtesy of 
Donald Milton.) The patient or research participant sits in the chair and breaths into the cone 
which draws air into the sampling system.
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Cough aerosol sampling system for collection of influenza aerosols. (Courtesy of William 
Lindsley.) With this system, the patient or research participant breaths and coughs into a 
mouthpiece connected to a spirometer. The aerosol particles expelled by the patient are then 
collected by an aerosol sampler (yellow and black) attached to the spirometer. The brown 
instrument on the outside is a vacuum pump that pulls air through the aerosol sampler.
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PneumoniaCheck™ device for point-of-care sampling of cough aerosols. (from Ku DN, Ku 
SK, Helfman B et al. Ability of device to collect bacteria from cough aerosols generated by 
adults with cystic fibrosis. F1000Research 2016, 5:1920 (doi: 0.12688/
f1000research.9251.1) When a patient coughs into the device, the air reservoir collects air 
and aerosol particles from the mouth and upper airways. When the air reservoir is full, the 
air and particles from the lower airways are then forced through the filter, which collects the 
particles. The filter is then removed for microbiological assays.
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